Welcome to our dedicated page for Celldex Therapeutics news (Ticker: CLDX), a resource for investors and traders seeking the latest updates and insights on Celldex Therapeutics stock.
Celldex Therapeutics, Inc. reports developments as a clinical-stage biotechnology company focused on mast cell biology and antibody-based therapeutics for allergic, inflammatory, autoimmune and other mast cell-mediated diseases. Company updates center on barzolvolimab, a humanized monoclonal antibody being studied across chronic spontaneous urticaria, cold urticaria and symptomatic dermographism, as well as pipeline work that includes CDX-622 in asthma.
Recurring news themes include clinical data presentations at allergy and dermatology meetings, financial results, corporate updates and capital actions. Celldex also reports financing activity tied to its common stock and development priorities for its antibody-based immunology pipeline.
Celldex Therapeutics, Inc. (Nasdaq:CLDX) has announced the promotion of Freddy A. Jimenez to Senior Vice President and General Counsel, effective January 1, 2021. With over 30 years of experience in the biopharmaceutical industry, Jimenez has significantly contributed to legal strategies supporting the company's R&D and business efforts since joining in 2016. His prior roles include 23 years at Johnson & Johnson, enhancing Celldex's legal compliance and regulatory framework. The leadership change is positioned as crucial for advancing a promising pipeline in 2021.
Celldex Therapeutics (Nasdaq: CLDX) has initiated its open-label clinical trial for CDX-0159, targeting cold contact urticaria and symptomatic dermographism. CDX-0159 is a humanized monoclonal antibody designed to inhibit the KIT receptor, crucial for mast cell activity. The trial aims to assess the drug's safety and clinical efficacy in patients resistant to antihistamines. Preliminary results are expected by Q1 2021. This advancement could address a significant unmet need in a condition affecting 0.5% of the population, positioning CDX-0159 as a potential disease-modifying treatment.
Celldex Therapeutics (NASDAQ:CLDX) will participate in a fireside chat at the 3rd Annual Evercore ISI HealthCONx Conference on December 2 at 4:20 PM ET. A webcast of the presentation will be available on their website, with a replay accessible for 14 days post-event. Celldex focuses on developing monoclonal and bispecific antibodies aimed at treating critical diseases, including inflammatory conditions and various cancers. For detailed information about Celldex's work, visit: www.celldex.com.
Celldex Therapeutics (NASDAQ:CLDX) presented significant updates at the SITC 2020 meeting. Data from the Phase 1 study of CDX-1140, an anti-CD40 monoclonal antibody, highlighted its potential as a best-in-class treatment, showing tumor shrinkage and necrosis in challenging cancer types. The company announced the initiation of expansion cohorts combining CDX-1140 with pembrolizumab and chemotherapy in various cancers. Additionally, CDX-527 and Axl-targeting programs were discussed, indicating ongoing commitment to advancing their innovative therapeutic pipeline.
Celldex Therapeutics (NASDAQ:CLDX) reported Q3 2020 financials, revealing a net loss of $14.2 million, or ($0.36) per share. Revenues increased to $0.7 million, driven by a milestone payment from Rockefeller University. The company initiated two Phase 1b studies for CDX-0159 in chronic spontaneous and inducible urticaria, alongside advancing bispecific candidate CDX-527. Despite cash reserves decreasing to $199.6 million, Celldex maintains that its funding is sufficient to meet operational needs through 2023.
Celldex Therapeutics (Nasdaq:CLDX) has initiated a Phase 1b clinical trial for CDX-0159, targeting chronic spontaneous urticaria (CSU). The trial, which is randomized and double-blind, will assess the safety and efficacy of multiple doses of CDX-0159 in approximately 40 patients with CSU unresponsive to antihistamines. Previous studies demonstrated CDX-0159's favorable safety profile and significant reductions in plasma tryptase levels, indicating its potential as a disease-modifying therapy. Results from the study are anticipated in the latter half of 2021.
Celldex Therapeutics (NASDAQ: CLDX) will participate in two upcoming virtual fireside chats. The first is at the Cantor Virtual Global Healthcare Conference on September 15, 2020, at 10:40 AM ET, followed by the HC Wainwright & CO 22nd Annual Global Investment Virtual Conference on September 16, 2020, at 9:00 AM ET. Webcasts of both presentations will be available on the Celldex website, with replays accessible for fourteen days post-event.
Celldex Therapeutics (Nasdaq: CLDX) has initiated enrollment for a Phase 1 open-label study of CDX-527, aimed at patients with advanced solid tumors. CDX-527 is a novel bispecific antibody designed to enhance anti-tumor T cell responses by combining PD-L1 blockade with CD27 costimulation. The trial will evaluate safety, maximum tolerated dose, and anti-tumor activity across various endpoints, enrolling approximately 90 patients. Previous data suggests CDX-527 could outperform existing treatments, bolstering its potential in the Celldex pipeline.
Celldex Therapeutics (Nasdaq: CLDX) is set to announce its second quarter 2020 financial results on August 6, 2020, after market close. A conference call will follow at 4:30 p.m. EDT, where executives will discuss the financial outcomes and provide updates on ongoing research and development initiatives for the remainder of 2020. The call will be accessible via the company’s website, and a replay will be available post-event. Celldex focuses on developing targeted therapeutics for severe diseases, utilizing immunotherapies and biologics to enhance treatment options for cancer and other illnesses.
Celldex Therapeutics (CLDX) has successfully closed an underwritten public offering of 15,384,614 shares at $9.75 each, generating approximately $150 million in gross proceeds. This includes the full exercise of the underwriters' option for additional shares. The company affirms that the funds will be sufficient to meet its working capital and operational needs through 2023. The offering was managed by Cantor Fitzgerald & Co., with H.C. Wainwright & Co. as co-manager. The offering is compliant with SEC regulations, and details are available on the SEC's website.